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Abstract
Background: As access to Xpert expands in high TB-burden settings, its performance against clinically diagnosed TB
as a reference standard provides important insight as the majority of childhood TB is bacteriologically unconfirmed. We
aim to describe the characteristics and outcomes of children with presumptive TB and TB disease, and assess
performance of Xpert under programmatic conditions against a clinical diagnosis of TB as a reference standard.
Methods: Retrospective review of children evaluated for presumptive TB in Mbeya, Tanzania. Baseline characteristics
were compared by TB disease status and, for patients diagnosed with TB, by TB confirmation status using Wilcoxon
rank sum test for continuous variables and the Chi-square test for categorical variables. Sensitivity and specificity were
calculated to assess the performance of Xpert, smear, and culture against clinical TB. Kappa statistics were calculated to
assess agreement between Xpert and smear to culture.
Results: Among children (N = 455) evaluated for presumptive TB, 70.3% (320/455) had Xpert and 62.8% (286/455) had
culture performed on sputa. 34.5% (157/455) were diagnosed with TB: 80.3% (126/157) pulmonary TB, 13.4% (21/157)
bacteriologically confirmed, 53.5% (84/157) HIV positive, and 48.4% (76/157) inpatients. Compared to the reference
standard of clinical diagnosis, sensitivity of Xpert was 8% (95% CI 4–15), smear 6% (95% CI 3–12) and culture 16% (95%
CI 9–24), and did not differ based on patient disposition, nutrition or HIV status.
Conclusion: Despite access to Xpert, the majority of children with presumptive TB were treated based on clinical
diagnosis. Reflecting the reality of clinical practice in resource limited settings, new diagnostics such as Xpert serve as
important adjunctive tests but will not obviate the need for astute clinicians and comprehensive diagnostic algorithms.
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Background
In 2014, one million cases of childhood tuberculosis (TB)
resulted in 140,000 pediatric deaths worldwide [1]. Diffi-
culties in diagnosing TB in children, coupled with the risk
of rapid, life-threatening progression of untreated disease,
make childhood TB a public health crisis in high TB
burden settings. Global data suggest that only 35% of
pediatric cases are diagnosed and notified [2]. The true
magnitude of childhood TB in high burden settings is
difficult to ascertain due to under-diagnosis and under-
reporting [3, 4]. Moreover in Tanzania only 23% of an
estimated 270,000 TB cases were notified in 2014, and
children comprised just 10% of these notified cases [1].
Firm diagnosis and confirmation of childhood TB re-
main challenging due to bacteriologic confirmation by
culture, the universally acknowledged reference stand-
ard, being suboptimal in children. In children, the sensi-
tivity of culture varies (range 1.5%–65%) depending on
age, disease severity, number of specimens collected and
disease prevalence of the setting [5–8]. The introduction
of the Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale,
CA, USA) brought promise as it showed improved sensi-
tivity, specificity and accuracy compared to smear
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microscopy in culture-positive pediatric cases [5, 9, 10].
Xpert was endorsed by World Health Organization
(WHO) as an initial diagnostic test in children, though
as a conditional recommendation with very low quality
of evidence [11]. However, when evaluated in respiratory
samples from culture-negative children started on anti--
tuberculosis therapy, Xpert sensitivity was only 2–4% [5,
11]. Due to the paucibacilllary nature of the disease in
children, the majority of childhood TB cases are smear
and culture negative, highlighting a potential limitation
when applying Xpert in these cases.
Subsequently, even with access to Xpert, the diagnosis
of childhood TB in high TB-burden countries such as
Tanzania relies upon the clinician’s ability to synthesize
symptoms, radiographic findings, TB exposure history,
and/or immunologic evidence of Mycobacterium tuber-
culosis infection. The use of a clinical TB diagnosis as a
reference standard against which to evaluate the per-
formance of diagnostic tests is an imperfect approach,
but it affords an important perspective on test perform-
ance in this setting. As Tanzania and other high TB-
burden countries roll out Xpert technology across
expanding levels of care, its performance in program-
matic conditions must be continually evaluated to effect-
ively inform policy makers. Upfront Xpert testing in
children has shown superior yield over smear micros-
copy [12, 13], but further assessment in children pre-
senting with a wide variety of disease manifestations in
varied settings is needed. In our retrospective descriptive
study, we described the characteristics and outcomes of
children with presumptive TB and TB disease, and
assessed the performance of Xpert under programmatic
conditions against a clinical diagnosis of TB as a refer-
ence standard. The approach was applied among
children with a range of disease severity in the context
of an outpatient pediatric clinic in Mbeya, Tanzania.
Methods
Ethical approval
Approval was obtained from all necessary ethical bodies
including the Mbeya Medical Research and Ethics
Committee and the National Institute of Medical Research
(NIMR) in Tanzania, and the Institutional Review Board,
Baylor College of Medicine, Houston, Texas, USA. Waiver
of consent was approved by all committees as this retro-
spective study analyzed only de-identified data.
Study setting
This retrospective descriptive study was conducted at
the Baylor College of Medicine Children’s Foundation –
Tanzania Centre of Excellence (COE) at Mbeya Zonal
Referral Hospital (MZRH), the single zonal referral
hospital for the Southern Highlands Zone of Tanzania,
with a catchment area serving over 3.2 million children
aged 0–14 years old [14]. The Southern Highlands Zone
reported more than 10% of Tanzania’s notified TB cases
[15]. The estimated burden of multidrug-resistant TB in
Tanzania is <1% [1]. The Mbeya COE is a family-
centered, pediatric prevention, care and treatment centre
offering comprehensive care to both HIV positive and
HIV negative children affected by TB, malnutrition and
other chronic conditions. A variety of different cadres,
including medical officers, nurses and paediatricians,
cared for patients at the COE. All clinicians undergo a
one month orientation on comprehensive pediatric care
(including childhood TB). The clinical pediatric experi-
ence varies among COE clinicians (e.g. medical officers
0–2 years; nurses 1–3 years; pediatricians 2–4 years). In
2011, in collaboration with the National Institute for
Medical Research-Mbeya Medical Research Center
(NIMR-MMRC) and MZRH, the COE expanded its
pediatric TB services to provide advanced diagnostics
(including Xpert) and comprehensive TB treatment initi-
ation and follow up.
Study population and clinical procedures
Retrospective data were collected on children (<15 years
of age) evaluated for presumptive TB and/or referred for
TB treatment between March 2013 and December 2014.
Clinicians used a combination of TB screening questions
(e.g. history of known TB contact, failure to gain weight/
weight loss, persistent cough, persistent fever, reduced
activities or irritability) and clinical examination findings
(e.g. malnutrition, lymphadenopathy, abnormal lung
findings), based on national guidelines [16], to identify
children with presumptive TB at the COE and in the
inpatient pediatric wards at MZRH. Presumptive TB
patients underwent diagnostics and evaluation at the
COE, including sputa analyzed by Xpert, smear, and cul-
ture, tuberculin skin testing (TST), chest x-ray (CXR),
and/or fine needle aspiration (FNA). Positive TST was
defined as TST ≥5 mm. Children unable to produce spu-
tum spontaneously completed sputum induction. The
NIMR-MMRC TB lab processed sputa samples as previ-
ously described [10]. Due to low volumes of collected
samples, smear and Xpert were performed routinely on
the first sample received, while culture was only per-
formed if a second sample was collected. Digital chest
radiography was interpreted by the clinician using the
Template Chest Radiography Review Tool [17] to assign
the following grades: ‘normal,’ ‘abnormal – suspicious for
TB’ (if evidence of lymphadenopathy, pleural effusion,
cavities, miliary patterns, and/or airspace consolidation)
and ‘abnormal – not TB’. FNA samples were collected in
patients with unexplained lymphadenopathy and were
sent to MZRH pathology department for histological re-
view. All diagnostic tests were performed prior to or on
the day of anti-tuberculosis treatment (ATT) initiation.
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TB diagnosis was based on a combination of clinical
history and findings, diagnostic results, and/or microbio-
logical or histological data. Children with confirmed or
clinically diagnosed TB were classified into one of three
predefined categories of diagnostic certainty (confirmed,
probable, possible TB), modeled after the internationally-
accepted consensus definition of intrathoracic childhood
TB [17] to also include EPTB (Table 1). Children with
alternative explanations for their symptoms and clinical
improvement without TB treatment were defined as “Not
TB.” All patient data were reviewed throughout the
22 month study period and all children who initiated ATT
were followed for the full 6 months of treatment to ensure
that children diagnosed with and treated for TB had a
positive treatment response and lacked an alternative,
non-TB explanation of their symptoms, and that children
classified as “Not TB” did not later developed TB. Treat-
ment outcomes were based on WHO definitions [18].
Statistical analysis
Data was extracted using a standardized data collection
tool and analyzed using Stata 12.1 SE software (Stata-
Corp2011, College Station, TX, USA). Baseline patient
characteristics were summarized using descriptive statis-
tics and compared by TB status (TB disease vs not TB
disease). For patients diagnosed with TB, baseline patient
characteristics were summarized using descriptive
statistics and compared by confirmation status (bacterio-
logically confirmed vs clinically diagnosed). Age was an-
alyzed using the Wilcoxon rank sum test, and all other
categorical baseline measures were analysed using the
Chi-square test to determine if these characteristics were
associated with TB disease or confirmation status as
appropriate. Children diagnosed with TB disease – either
confirmed, possible or probable TB – were classified as
“clinical TB”, which served as our primary reference
standard (and incorporated both CXR and TST results).
Sensitivity and specificity were calculated to assess the
performance of Xpert, smear, and culture against clinical
TB. Test performances were analyzed for all children
and subgroups. Patients who did not have diagnostic
tests performed or did not have recorded results (e.g.
error/invalid) were excluded from calculations. The
Kappa statistic, overall agreement, positive agreement
and negative agreement were calculated to assess agree-
ment between the three tests [19] for patients who had a
positive or negative test result for all three tests.
Results
Between March 2013 and December 2014, 455 children
with presumptive TB were evaluated. Of those, 157 (34.5%)
were diagnosed with TB. Baseline characteristics and diag-
nostic tests performed among those diagnosed with and
without TB did not differ, with the exception of FNA being
performed more often in those with TB compared to
without [8.3% (13/157) vs 3.7% (11/298), p = 0.035;
Table 2]. Final diagnostic certainty categories were
13.4% (21/157) bacteriologically confirmed TB, 63.1%
(99/157) probable TB, and 23.6% (37/157) possible TB
(Table 3). The majority of children had pulmonary
TB (80.3%, 126/157). Bacteriologically confirmed TB
cases were older (median age 9.4 years vs 4.6 years,
p = 0.017) and more likely to provide sputum for
analysis [100% (21/21) vs 69.1% (94/136), p = 0.001]
compared to clinically diagnosed TB cases (Table 4).
Ninety-nine percent (155/157) of children with a TB
diagnosis were initiated on ATT, with one child dying
and one child lost-to-follow up (LTFU) before treatment
could be initiated. Sixty-nine percent of children (109/
157) showed treatment success, 7.0% (11/157) were not
evaluated/transferred out, 7.6% (12/157) died and 15.9%
(25/157) were LTFU (Table 3). All children followed
through the completion of their treatment showed posi-
tive clinical response to TB treatment for the duration of
their follow up.
Among those producing an initial sputum (n = 320),
2.8% of children (9/320, 95% CI 1.3–5.3) had a positive
Xpert and 2.2% of children (7/320, 95% CI 0.9–4.5) had
a positive smear (Figure 1). Culture was positive in 5.6%
(16/286, 95% CI 3.2–8.9) of those producing a second
sputum. Xpert was positive in 7.1% (4/56, 95% CI 2.0–
Table 1 Diagnostic certainty categories for cases of TB disease
in childrena
Diagnostic Certainty Group Definition of Case Categories
Confirmed tuberculosis A child with Mycobacterium tuberculosis
identified from a clinical specimen using
any microbiologic diagnostic test available
(e.g. smear, culture, or Xpert) and at least
one sign or symptom suggestive of
tuberculosis
Probable tuberculosis A child with one or more of the following
clinical symptoms:
• Abnormal CXR consistent with TB
• Cough duration greater than 2 weeks
• Weight loss or failure to thrive
(WHZ-score less than −2)
• Fever greater than 2 weeks
• Signs/symptoms of disseminated TB
And one (or more) of the following:
• Documented exposure to TB in the
preceding 24 months
• A positive clinical response to anti-
tuberculosis treatment
• Immunologic (TST or IGRA) evidence of
Mycobacterium tuberculosis infection
Possible tuberculosis A child with one or more of the following
clinical symptoms:
• Abnormal CXR consistent with TB
• Cough greater than 2 weeks
• Weight loss or failure to thrive
(WHZ-score less than –2)
• Fever greater than 2 weeks
aAdapted from Graham et al. [17]
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17.3) of the no sample for culture TB cases and none
(0/85, 95% CI 0.0–4.2) of the culture negative TB
cases. No rifampicin resistance was detected by Xpert.
When compared to a reference standard of clinical
diagnosis, the sensitivities of culture, Xpert and smear
were 16% (95% CI 9–24), 8% (95% CI 4–15), and 6%
(95% CI 3–12), respectively. The sensitivity of culture,
Xpert and smear did not significantly vary by inpatient
versus outpatient disposition or by HIV-status (Figure 2).
Specificity of culture, Xpert, and smear was high in all
groups when using ‘clinical TB’ as reference standard
(range of 0.99–1.00, 95% CIs 0.95–1.00). Kappa statistics
for level of agreement demonstrated higher agreement
for Xpert and culture compared to agreement for smear
and culture in all patients and subgroups with the excep-
tion of HIV negative children (Table 5; see Additional
File 1 for comparison of Xpert and clinical TB to the
culture as reference standard).
TST and CXR was performed in 89.5% (407/455) and
62.2% (283/455), respectively, of children with presump-
tive TB. Overall, 13.5% (55/407) of TSTs were positive
and 23.3% (66/283) of CXR were resulted as ‘abnormal –
suspicious for TB’ (see Additional File 2 for positivity
rates of TST and CXR among subgroups). HIV positive
children were more likely to have sputum analysis
(76.6% vs 62.5%, p = 0.001) and less likely to have TST
done (86.6% vs 92.8%, p = 0.03), compared to HIV nega-
tive children. There were no differences in CXR or FNA
performed between the two groups.
Discussion
Our study demonstrated that among Tanzanian children
receiving care at a pediatric clinic in a resource-
constrained setting, the yield of Xpert against a clinical
diagnosis of TB was limited. When compared to this
Table 2 Baseline characteristics of patients referred for presumptive TB (N = 455)
TB diseasea (n = 157) Not TB disease (n = 298) p-value
Median age in years at time of TB referral (IQR) 5.0 (1.6 – 9.5) 4.4 (1.5 – 10.0) 0.872
Male gender (%) 75 (47.8) 139 (46.6) 0.819
HIV positive (%) 84 (53.5) 163 (54.7) 0.808
Disposition at time of referral of “Inpatient” (%) 76 (48.4) 142 (47.7) 0.878
Past TB treatment (%) 7 (4.5) 9 (3.0) 0.428
Severe Malnutrition (%)b 50 (31.9) 119 (39.9) 0.090
Reported TB contact (%) 33 (21.0) 52 (17.5) 0.353
Diagnostic Tests Performed
Sputum analysis (%) 115 (73.3) 205 (68.8) 0.323
Chest x-ray (%) 107 (68.2) 176 (59.1) 0.057
Tuberculin skin test (%) 143 (91.1) 264 (88.6) 0.411
Fine needle aspirate (%) 13 (8.3) 11 (3.7) 0.037
aTB disease includes all children meeting criteria for confirmed, possible or probable TB. bSevere acute malnutrition is defined as weight-for-height Z score < 3 SD
and/or presence of edema [29]
Table 3 Characteristics and treatment outcomes of children
diagnosed with TB (N = 157)
Characteristic Number %
Treatment Initiation
ATT initiated 155 998.7%
Median time from referral to initiation of
ATT (days, IQR)
3 days 1.00–6.25 days
Diagnostic Certainty
Confirmed TB 21 13.4%
Confirmed pulmonary TB 20 95.2%
Confirmed EPTB 1 4.8%
Confirmed LNTB 0 0.0%
Probable TB 99 63.1%
Possible TB 37 23.6%
Type of TB
Pulmonary TB 126 80.3%
EPTB (excluding lymph node TB) 19 12.1%
Lymph node TB 12 7.6%
Treatment Outcomes
Cureda 19 12.1%
Treatment Completedb 90 57.3%
Transferred Out/Not Evaluated 11 7.0%
Died 12 7.6%
Lost-to-follow up 25 15.9%
Abbreviations: ATT, anti-tuberculosis therapy; EPTB, extrapulmonary TB; LNTB,
lymph node TB
aCured = bacteriologically confirmed TB at the beginning of treatment who
was smear- or culture-negative in the last month of treatment and on at least
one previous occasion. bTreatment Completed = clinically diagnosed or
bacteriologically confirmed TB patient who completed treatment without
evidence of failure, but with no record of sputum smear or culture results in the
last month of treatment were negative, either because tests were not done or
because no results available [18]
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reference standard, the sensitivity of Xpert was 8%.
Although marginally better than smear (6% sensitivity),
Xpert was half as sensitive as culture (16% sensitivity).
Large proportions of children with presumptive TB pre-
sented in a severely compromised state with multiple co-
morbidities (54.3% HIV positive, 47.9% hospitalized,
37.1% severely malnourished). This likely lowered
clinicians’ thresholds for empiric TB treatment and
contributed to the high numbers of clinical TB diagnoses
(86.7% of TB cases). Our findings demonstrate that even
with access to Xpert, TB treatment decisions rely heavily
on clinical diagnosis, particularly in critically ill children.
The effect and interplay between Xpert and empiric TB
treatment remains complex [20], and our findings high-
light the limitations of Xpert when used in children
diagnosed with culture-negative (or not performed) TB in
Table 4 Baseline characteristics of clinically diagnosed versus bacteriologically confirmed TB patients (N = 157)





Median age in years at time of TB referral (IQR) 4.6 (1.5 – 9.1) 9.4 (4.5–12.1) 0.017
Male gender (%) 68 (50.0) 14 (66.7) 0.155
HIV positive (%) 73 (53.7) 11 (52.4) 0.912
Disposition at time of referral of “Inpatient” (%) 69 (50.7) 7 (33.3) 0.137
Past TB treatment (%) 5 (3.7) 2 (9.5) 0.237
Severe Malnutrition (%)b 42 (30.9) 8 (38.1) 0.509
Reported TB contact (%) 28 (20.6) 5 (23.8) 0.736
Diagnostic Tests Performed
Sputum analysis (%) 94 (69.1) 21 (100.0) 0.001
Chest x-ray (%) 91 (66.9) 16 (76.2) 0.460
Tuberculin skin test (%) 123 (90.1) 20 (95.2) 0.695
Fine needle aspirate (%) 13 (100.0) 0 (0.0) 0.218
aBacteriologically confirmed TB is a TB case from whom a biological specimen is positive by smear microscopy, culture or Xpert MTB/RIF. bSevere acute
malnutrition is defined as weight-for-height Z score <3 SD and/or presence of edema [29]
Fig. 1 Sputum analyses performed and sputum results for children with presumptive TB
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a high burden setting. Our estimates of Xpert sensitivity
are consistent with previous research comparing the per-
formance of Xpert to clinical diagnosis in culture-negative
pediatric cases [5, 21, 22], as well as an earlier prospective
study in our same study setting [10] that demonstrated
8.5% sensitivity of Xpert in children clinically diagnosed
with TB. While that study evaluated three sputa samples
for every patient, our programmatic approach allowed a
maximum of one sputum sample for culture. The use of
multiple sputum samples improves Xpert test perform-
ance [10, 23], however this approach is not feasible in our,
nor in many other, resource-constrained settings. A
thoughtful comparison of these differences further high-
lights the reality and challenges of TB diagnostics, care
and treatment of children presenting in the clinical care
arena rather than a research setting.
Emerging evidence suggests under-diagnosis of TB may
be common in children with severe acute malnutrition
(SAM) and/or HIV and their mortality is high [7, 24, 25].
We were able to evaluate TB diseased children who pre-
sented with a wide spectrum of disease severity and co-
morbidities – including HIV co-infection, SAM, and in-
patient disposition – and were unable to show a difference
in performance of Xpert in children based on their HIV,
malnutrition, or inpatient status. We postulate that in
these children clinicians have lower thresholds for empiric
TB treatment, and their TB infection may have progressed
more rapidly to severe disease, despite lower, undetectable
mycobacterial loads.
The impact of any new diagnostic test – such as Xpert
– depends greatly on how it is implemented outside of
research settings and on the context in which it is imple-
mented [26]. Two recent randomized controlled trials
evaluating the impact of Xpert in adults in high TB bur-
den settings showed that despite increased sensitivity
and decreased turnaround time, its use did not translate
Fig. 2 Sensitivities of smear, Xpert and culture among all patients and subgroups using “clinical TB” as the primary reference standard (with error
bars representing 95% CIs)
Table 5 Agreement and discordance of culture versus Xpert and smear stratified by referral type and HIV status

















All children 270/282 45.5/97.8 95.7 0.44 (0.18–0.70) 268/282 95.0 36.4/97.4 0.35 (0.09–0.60)
Inpatient 105/106 66.7/99.5 99.1 0.66 (0.04–1.00) 104/106 98.1 50.0/99.0 0.49 (–0.12–1.00)
Outpatient 165/176 42.1/96.7 93.8 0.40 (0.13–0.67) 164/176 93.2 33.3/96.4 0.31 (0.04–0.59)
HIV positive 160/167 53.3/97.8 95.8 0.52 (0.21–0.82) 157/167 94.0 28.6/96.9 0.27 (−0.04–0.57)
HIV negative 110/115 28.6/97.8 95.7 0.28 (−0.15–0.70) 111/115 96.5 50.0/98.2 0.49 (0.06–0.91)
PA = Positive Agreement, NA = Negative agreement
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into patient important outcomes such as reduced mor-
bidity or mortality [27, 28]. Xpert is particularly useful
when positive in pediatric cases where a clinical diagno-
sis is unclear. However, a negative Xpert result cannot
exclude the possibility of TB disease, especially in chil-
dren living in areas of high TB burden. In our setting,
the majority of childhood TB cases were still diagnosed
clinically, demonstrating how, even though Xpert is a
valuable additional test in children, it is not a stand-
alone replacement to culture and clinical diagnosis.
Clinicians must be made aware of these limitations and
resources should be utilized to strengthen all compo-
nents of the diagnostic algorithm in concert.
Our study was limited by its retrospective approach
assessing TB care at a single site. Despite clinical prac-
tice following national guidelines, there was variability in
the diagnostic tests performed per patient, reflecting the
reality of clinical practice in TB high burden, resource
constrained settings. This variability provided unique
and realistic insights regarding the incorporation of new
diagnostics into clinical care. Our site received many re-
ferrals, contributing to potential referral bias that low-
ered clinicians’ thresholds to treat empirically. High
levels of empiric treatment may limit the performance of
Xpert against clinical practice. Although there were few
bacteriologically confirmed cases, our study benefited
from long follow up of at least six months of all patients
to ensure that clinically diagnosed TB cases improved
on ATT and ‘not TB’ cases improved without ATT. Our
study did not specifically look at impact of Xpert on
clinician behavior or favorable patient outcomes, but
provided the basic foundation for such future research.
Overall, these findings emphasize the importance of
evaluating new diagnostics in children against clinical
diagnosis as reference standards.
Conclusion
Despite access to Xpert technology, the majority of
childhood TB cases presenting to a pediatric referral
centre in a resource limited setting were diagnosed clin-
ically, thus limiting the contribution of Xpert to clinical
decision making under our programmatic conditions.
Recognizing the paucibacillary nature of childhood TB
and high risk of rapid disease progression in children,
new diagnostics such as Xpert serve as important ad-
junctive tests but will not obviate the need for astute cli-
nicians and comprehensive diagnostic algorithms. Care
should be taken to carefully balance allocation of scarce
resources between new diagnostic technologies (e.g.
Xpert) and educational efforts to foster traditional
components of the diagnostic algorithm (e.g. history,
physical exam, radiography, TST) for childhood TB in
resource limited settings.
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